Overview

• Survey finds 12% of U.S. adults have used GLP-1 drugs, with significant usage among diabetics and heart disease patients.
• High cost remains a barrier, with over half of users reporting difficulties in affording these medications.
• Medicare coverage debated as majority supports inclusion for weight loss prescriptions amid regulatory restrictions.
• Drug shortages persist as manufacturers struggle to meet the high demand for popular GLP-1 drugs like Wegovy.
• Public awareness of GLP-1 medications has increased, with many seeking them for both approved and off-label uses.